NCT05657210

Prognostic Value of Each Codon-specific KRAS Mutation in Colorectal Cancer

Does KRAS Codon 13 Mutation Have Prognostic Value in Colorectal Cancer?

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,203 (actual)
• Sponsor: Seoul National University Bundang Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

This retrospective study reviewed 3,144 patients who underwent surgery for colorectal cancer. This study was designed to comprehend the clinicopathological characteristics associated with individual codon-specific KRAS mutations in colorectal cancer.

Detailed description

This study was designed to comprehend the clinicopathological characteristics associated with individual codon-specific KRAS mutations in colorectal cancer including codon 12, 13, and 61. Furthermore, the main objective of this study was to determine whether KRAS codon 13 mutation could serve as a prognostic biomarker of colorectal cancer in a relatively large cohort of subjects. Overall survival (OS) and recurrence-free survival (RFS) were calculated from the date of surgery and compared using the Kaplan-Meier method and log-rank test. For analysis of risk factors for tumor recurrence, Cox proportional hazards regression model was used with the covariance input criterion set as \< 0.1. Patients were subdivided based on primary tumor location (colon versus rectum), and MSI status (MSS/MSI-low versus MSI-high).

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
GENETIC	Mutation

Timeline

• Start date: 2009-01-01
• Primary completion: 2021-12-31
• Completion: 2021-12-31
• First posted: 2022-12-20
• Last updated: 2022-12-20

Locations

1 site across 1 country: South Korea